Healthcare
GE HealthCare Technologies Inc.(GEHC)
Live Price
Offline$65.76
+1.26% today
1Y Change
-18.47%
Window
Jun 27, 2025 โ Jun 22, 2026
- Market Cap
- $27.35B
- Revenue Growth
- +4.8%
- EPS Growth
- +4.3%
- Dividend Yield
- 0.2%
Coverage: 246 bars ยท Jun 27, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GE HealthCare Technologies Inc. (GEHC) is a Healthcare stock with a market cap of $27.35B and listed on NASDAQ. The stock last traded around $65.76 and down 18.5% across the available one-year price window (Jun 27, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +4.8%, EPS growth of +4.3%, a dividend yield of 0.2%. What stands out right now is revenue +4.8%, EPS +4.3%, free cash flow -2.8% with operating margin 12.5% and ROIC 8.9%. The dividend is present but secondary, with a yield around 0.2%. Valuation is more restrained than many high-expectation growth names at P/E 18.2 and price/sales 1.4. Stock Foundry combines GEHC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.8% vs +7.6% peer median
Operating Margin
Below sector median
+12.5% vs +19.4% peer median
P/E
Below sector median
18.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.8% and EPS at +4.3%, with operating margin around 12.5%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | +2.3% | +3.8% | +5.7% |
2026 Feb 4, 2026 | +2.9% | -0.4% | -4.2% | -6.7% |
2025 Oct 29, 2025 | +1.9% | -3.1% | -2.3% | +4.2% |
Benchmark Edge
GEHC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GEHC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GEHC Max Drawdown
-32.53%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GEHC and SPY.
Company Overview
GE HealthCare Technologies Inc.
NASDAQ Global Select
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
- Leadership
- Peter J. Arduini
- IPO Date
- Dec 15, 2022
- Employees
- 53.0k
- Street Address
- 500 West Monroe Street
- Mailing
- Chicago, IL, 60661
- Region
- Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 833 735 1139
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.2
- EV/EBITDA
- 7.9
- Price/Sales
- 1.4
- Price/Book
- 2.6
Growth
- Revenue
- +4.8%
- EPS
- +4.3%
- Free Cash Flow
- -2.8%
Profitability
- Gross Margin
- 42.5%
- Operating Margin
- 12.5%
- Net Margin
- 7.5%
- ROE
- 14.8%
- ROIC
- 8.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 0.99
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.